Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Product Type
2.3.2 Market Size By Mechanism
2.3.3 Market Size By End-User
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Production Capacity & Utilization Metrics
4.1.1 Average manufacturing capacity (billion tablets/capsules per year) across major CMOs
4.1.2 Capacity utilization rate (%) for OSD contract manufacturing facilities
4.1.3 Share (%) of high-volume vs. small-batch OSD production
4.2 Outsourcing & Demand Indicators
4.2.1 Percentage of pharmaceutical companies outsourcing OSD formulation and manufacturing
4.2.2 Growth rate (%) of outsourcing demand from small & emerging pharma
4.2.3 Proportion of generic vs. branded drugs in outsourced OSD production
4.3 Quality Compliance & Regulatory Metrics
4.3.1 Number and percentage of OSD CMO facilities with FDA/EMA/WHO GMP approvals
4.3.2 Annual frequency of quality audits per contract manufacturer
4.3.3 Percentage of batches rejected or reprocessed due to quality deviations
4.4 Cost & Efficiency Statistics
4.4.1 Average cost reduction (%) achieved by pharma companies via OSD outsourcing
4.4.2 Lead time reduction (days/weeks) due to advanced manufacturing technologies
4.4.3 Average turnaround time for OSD formulation-to-production cycles
5. Oral Solid Dosage Contract Manufacturing Market Segmental Analysis & Forecast, By Product Type, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Tablets
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Capsules
5.4 Powders
5.5 Granules
5.6 Others
6. Oral Solid Dosage Contract Manufacturing Market Segmental Analysis & Forecast, By Mechanism, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Immediate Release
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Delayed Release
6.4 Controlled Release
7. Oral Solid Dosage Contract Manufacturing Market Segmental Analysis & Forecast, By End-User, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 Large Size Companies
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Medium & Small Size Companies
7.4 Others
8. Oral Solid Dosage Contract Manufacturing Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)
8.1 Introduction
8.2 North America
8.2.1 Key Trends
8.2.2 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Product Type, 2021 – 2032
8.2.3 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Mechanism, 2021 – 2032
8.2.4 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By End-User, 2021 – 2032
8.2.5 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Country, 2021 – 2032
8.2.5.1 USA
8.2.5.2 Canada
8.3 Europe
8.3.1 Key Trends
8.3.2 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Product Type, 2021 – 2032
8.3.3 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Mechanism, 2021 – 2032
8.3.4 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By End-User, 2021 – 2032
8.3.5 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Country, 2021 – 2032
8.3.5.1 Germany
8.3.5.2 UK
8.3.5.3 France
8.3.5.4 Italy
8.3.5.5 Spain
8.3.5.6 Russia
8.3.5.7 Poland
8.3.5.8 Rest of Europe
8.4 Asia-Pacific
8.4.1 Key Trends
8.4.2 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Product Type, 2021 – 2032
8.4.3 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Mechanism, 2021 – 2032
8.4.4 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By End-User, 2021 – 2032
8.4.5 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Country, 2021 – 2032
8.4.5.1 China
8.4.5.2 India
8.4.5.3 Japan
8.4.5.4 South Korea
8.4.5.5 Australia
8.4.5.6 ASEAN Countries
8.4.5.7 Rest of Asia-Pacific
8.5 Latin America
8.5.1 Key Trends
8.5.2 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Product Type, 2021 – 2032
8.5.3 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Mechanism, 2021 – 2032
8.5.4 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By End-User, 2021 – 2032
8.5.5 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Country, 2021 – 2032
8.5.5.1 Brazil
8.5.5.2 Argentina
8.5.5.3 Mexico
8.5.5.4 Colombia
8.5.5.5 Rest of Latin America
8.6 Middle East & Africa
8.6.1 Key Trends
8.6.2 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Product Type, 2021 – 2032
8.6.3 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Mechanism, 2021 – 2032
8.6.4 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By End-User, 2021 – 2032
8.6.5 Oral Solid Dosage Contract Manufacturing Market Size & Forecast, By Country, 2021 – 2032
8.6.5.1 UAE
8.6.5.2 Saudi Arabia
8.6.5.3 Qatar
8.6.5.4 Egypt
8.6.5.5 South Africa
8.6.5.6 Rest of Middle East & Africa
9. Competitive Landscape
9.1 Key Players' Positioning
9.2 Competitive Developments
9.2.1 Key Strategies Adopted (%), By Key Players, 2024
9.2.2 Year-Wise Strategies & Development, 2021 – 2025
9.2.3 Number Of Strategies Adopted By Key Players, 2024
9.3 Market Share Analysis, 2024
9.4 Product/Service & Application Benchmarking
9.4.1 Product/Service Specifications & Features By Key Players
9.4.2 Product/Service Heatmap By Key Players
9.4.3 Application Heatmap By Key Players
9.5 Industry Start-Up & Innovation Landscape
9.6 Key Company Profiles
9.6.1 Catalent, Inc.
9.6.1.1 Company Overview & Snapshot
9.6.1.2 Product/Service Portfolio
9.6.1.3 Key Company Financials
9.6.1.4 SWOT Analysis
9.6.2 Lonza Group AG
9.6.3 Thermo Fisher Scientific
9.6.4 Recipharm AB
9.6.5 Cambrex Corporation
9.6.6 Piramal Pharma Solutions
9.6.7 Almac Group
9.6.8 Aenova Group
9.6.9 Famar Health Care Services
9.6.10 Strides Pharma Science Ltd.
9.6.11 Corden Pharma International
9.6.12 Siegfried Holding AG
9.6.13 NextPharma
9.6.14 Jubilant Pharmova Limited
9.6.15 Boehringer Ingelheim International GmbH
9.6.16 Fareva Holding SA
9.6.17 Hetero Drugs Limited
9.6.18 Pfizer CentreOne
9.6.19 Evonik Industries AG
9.6.20 Akums Drugs and Pharmaceuticals Limited
10. Analyst Recommendations
10.1 SNS Insider Opportunity Map
10.2 Industry Low-Hanging Fruit Assessment
10.3 Market Entry & Growth Strategy
10.4 Analyst Viewpoint & Suggestions On Market Growth
11. Assumptions
12. Disclaimer
13. Appendix
13.1 List Of Tables
13.2 List Of Figures
